Tango Therapeutics
Yahoo Finance • 6 days ago
Most shorted stocks on Wall Street
[short sale] abluecup As October begins, investors are keeping a close eye on heavily shorted stocks that could see heightened volatility. The latest mid- to mega-cap screen shows 39 stocks with short interest above 20% of shares outstan... Full story
Yahoo Finance • last month
Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?
It has been about a month since the last earnings report for Tango Therapeutics, Inc. (TNGX). Shares have lost about 6.2% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earn... Full story
Yahoo Finance • last month
RVMD Secures FDA Win, Gets Nod for Rasonque in Pancreatic Cancer
Revolution Medicines RVMD announced that the FDA has approved its RAS inhibitor daraxonrasib for previously treated patients with metastatic pancreatic ductal adenocarcinoma (PDAC). The drug will be marketed under the brand name Rasonque.... Full story
Yahoo Finance • 2 months ago
Most and least shorted mid- to mega-cap healthcare stocks at the end of July
[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images Short interest data from late July 2026 highlights deeply divided investor sentiment across the healthcare sector. S... Full story
Yahoo Finance • 3 months ago
Tango Therapeutics (TNGX) to Benefit From Vopimetostat + KRAS Inhibitors Combined Revenues
Tango Therapeutics Inc. (NASDAQ:TNGX) is one of the 10 affordable biotech stocks to buy right now. On June 29, Canaccord Genuity increased its target price on Tango Therapeutics Inc. (NASDAQ:TNGX) from $42 to $46, resulting in more than 5... Full story
Yahoo Finance • 4 months ago
Tango Appoints Robert Azelby To Board Of Directors
(RTTNews) - Tango Therapeutics, Inc. (TNGX), a clinical-stage biotechnology company, announced the appointment of Robert Azelby to its Board of Directors. Azelby brings more than 30 years of experience in executive management, commercial... Full story
Yahoo Finance • 4 months ago
Tango Therapeutics prices upsized $600M public offering at $30/share
Tango Therapeutics (TNGX [https://seekingalpha.com/symbol/TNGX]) announced the pricing [https://seekingalpha.com/pr/20546196-tango-therapeutics-announces-pricing-of-600-million-upsized-public-offering] of an upsized underwritten public off... Full story
Yahoo Finance • 4 months ago
Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering
BOSTON, June 09, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (“Tango”) (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, announced toda... Full story
Yahoo Finance • 4 months ago
Quant rating check: Top oncology peers as Nuvalent goes private in $10.6B deal with GSK
The targeted oncology sector is shifting after GSK (GSK [https://seekingalpha.com/symbol/GSK]) decided to buy [https://seekingalpha.com/news/4601644-gsk-to-buy-nuvalent-for-106b] Nuvalent (NUVL [https://seekingalpha.com/symbol/NUVL]) for $... Full story
Yahoo Finance • 4 months ago
Sector Update: Healthcare Stocks Decline Late Afternoon
Healthcare stocks were lower late Monday afternoon, with the NYSE Healthcare Index shedding 0.4% and PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story
Yahoo Finance • 4 months ago
Pre-Market Movers: TNGX, WOK, GOCO Set The Path
(RTTNews) - Biotech companies are seeing significant pre-market activity this Monday, hinting at possible breakout opportunities. Assessing sentiment and momentum in the premarket sets the tone for a trader's day. Price swings ahead of t... Full story
Yahoo Finance • 4 months ago
Tango Therapeutics (TNGX) Could Benefit From Pancreatic Ductal Adenocarcinoma Data Announcement
Tango Therapeutics Inc. (NASDAQ:TNGX) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds. On May 15, the price target on Tango Therapeutics Inc. (NASDAQ:TNGX) was increased from $28 to $55 by Leerink. Follo... Full story
Yahoo Finance • 4 months ago
Here is Why Erasca (ERAS) is One of the Best Growth Stocks Under $20
Erasca Inc. (NASDAQ:ERAS) is one of the best growth stocks under $20 to buy. On May 11, Erasca reported positive progress for its precision oncology pipeline, highlighting monotherapy efficacy and a favorable safety profile for its lead ca... Full story
Yahoo Finance • 5 months ago
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase
On May 15, 2026, Boxer Capital Management disclosed a new position in Corvus Pharmaceuticals(NASDAQ:CRVS), acquiring 1,100,000 shares in the first quarter for an estimated $17.55 million based on quarterly average pricing. What happened... Full story
Yahoo Finance • 5 months ago
Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally
Boxer Capital Management increased its stake in Kodiak Sciences(NASDAQ:KOD) during the first quarter, adding 225,000 shares in a transaction estimated at $5.81 million based on quarterly average pricing, according to a May 15, 2026, SEC fi... Full story
Yahoo Finance • 5 months ago
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares
On May 15, 2026, Boxer Capital Management disclosed a purchase of 1,241,000 Vir Biotechnology(NASDAQ:VIR) shares, an estimated $9.89 million trade based on quarterly average pricing. What happened According to a Securities and Exchange C... Full story
Yahoo Finance • 5 months ago
Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy
What happened According to an SEC filing dated May 15, 2026, Acuta Capital Partners, LLC initiated a new position in Erasca(NASDAQ:ERAS) during the first quarter. The fund acquired 354,575 shares, with an estimated transaction value of $4... Full story
Yahoo Finance • 5 months ago
Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
First clinical data from PRMT5/RAS(ON) combination trial to be presented in 2026 Cash position of $380 million as of March 31, 2026, with runway into 2028 beyond anticipated key data inflection points BOSTON, May 13, 2026 (GLOBE NEWSWI... Full story
Yahoo Finance • 5 months ago
Stifel Remains Bullish on Tango Therapeutics (TNGX)
Tango Therapeutics, Inc. (NASDAQ:TNGX) is one of the best performing healthcare stocks so far in 2026. Stifel lifted the price target on Tango Therapeutics, Inc. (NASDAQ:TNGX) to $40 from $24 on April 27, maintaining a Buy rating on the sh... Full story
Yahoo Finance • 5 months ago
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that effective May 1, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors granted (i) a non-qualified stock option t... Full story